[1] Arnaldi
G, Mancini T, Tirabassi G, et al. Advances in the epidemiology, pathogenesis,
and management of Cushing's syndrome complications [J]. J Endocrinol Invest,
2012, 35(4):434-448. DOI: 10.1007/BF03345431.
[2] Zhou J, Zhang M, Bai X, et al.
Demographic characteristics, etiology, and comorbidities of patients with
Cushing's syndrome: a 10-year retrospective study at a large general hospital
in China [J]. Int J Endocrinol, 2019, 2019:7159696. DOI: 10.1155/2019/7159696.
[3] Valassi E, Santos A, Yaneva M, et al.
The European Registry on Cushing's syndrome: 2-year experience. Baseline
demographic and clinical characteristics [J]. Eur J Endocrinol, 2011,
165(3):383-392. DOI: 10.1530/EJE-11-0272.
[4] Rahaman SH, Jyotsna VP, Kandasamy D, et
al. Bone health in patients with Cushing's syndrome [J]. Indian J Endocrinol
Metab, 2018, 22(6): 766-769. DOI: 10.4103/ijem.IJEM_160_18.
[5] 李巧,姚军,吴红花,等.库欣综合征合并骨质疏松症患者的临床特点及骨密度相关因素分析[J].中国骨质疏松杂志,2018,24(8):1034-1039,1048.
DOI:10.3969/j.issn.1006- 7108.2018.08.011.
[6] Mancini T, Doga M, Mazziotti G, et al.
Cushing's syndrome and bone [J]. Pituitary, 2004, 7(4): 249-252. DOI:
10.1007/s11102-005-1051-2.
[7] Canalis E, Bilezikian JP, Angeli A, et
al. Perspectives on glucocorticoid-induced osteoporosis [J]. Bone, 2004,
34(4):593-598. DOI: 10.1016/j.bone.2003.11.026.
[8] 居家宝,张培训.库欣综合征伴多发骨折1例报道及文献回顾[J].实用骨科杂志,2019,25(3):283-285.
[9] Kaltsas G, Makras P. Skeletal diseases
in Cushing's syndrome: osteoporosis versus arthropathy [J]. Neuroendocrinology,
2010, 92 Suppl 1: 60-64. DOI: 10.1159/000314298.
[10] Seibel MJ, Cooper MS, Zhou H.
Glucocorticoid-induced osteoporosis: mechanisms, management, and future
perspectives [J]. Lancet Diabetes Endocrinol, 2013, 1(1):59-70. DOI:
10.1016/S2213-8587(13)70045-7.
[11] Braun LT, Fazel J, Zopp S, et al. The
effect of biochemical remission on bone metabolism in Cushing's syndrome: a
2-year follow-up study [J]. J Bone Miner Res, 2020, 35(9):1711-1717. DOI:
10.1002/jbmr.4033.
[12] Canalis E, Mazziotti G, Giustina A, et
al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy [J].
Osteoporos Int, 2007, 18(10): 1319-1328. DOI: 10.1007/s00198-007-0394-0.
[13] O'Brien CA, Jia D, Plotkin LI, et al.
Glucocorticoids act directly on osteoblasts and osteocytes to induce their
apoptosis and reduce bone formation and strength [J]. Endocrinology, 2004,
145(4): 1835-1841. DOI: 10.1210/en.2003-0990.
[14] 李云凤,裴育,谷伟军,等.库欣综合征患者手术前后骨转换标志物的变化[J].国际医药卫生导报,2018,24(6):867-870. DOI:10.3760/cma.j.issn.1007-1245.2018.06.024.
[15] Di Somma C, Pivonello R, Loche S, et al.
Effect of 2 years of cortisol normalization on the impaired bone mass and
turnover in adolescent and adult patients with Cushing's disease: a prospective
study [J]. Clin Endocrinol (Oxf), 2003, 58(3):302-308. DOI:
10.1046/j.1365-2265. 2003.01713.x.
[16] 宁翠利,刘宽芝.以严重低血钾为首发症状的垂体促肾上腺皮质激素瘤一例报告并文献复习[J].中国全科医学,2016,19(31):3888-3889,3890. DOI:10.3969/j.issn.1007-9572.
2016.31.027.
[17] Frey FJ, Odermatt A, Frey BM. Glucocorticoid-mediated
mineralocorticoid receptor activation and hypertension [J]. Curr Opin Nephrol
Hypertens, 2004, 13(4): 451-458. DOI: 10.1097/01.mnh.0000133976.32559.b0.
[18] 连鹏鹄,李汉忠,张玉石,等.11β-羟基类固醇脱氢酶2型活性对库欣综合征患者血钾水平的影响[J].中华医学杂志,2015,95(12):929-932. DOI:10.3760/cma.j.issn.0376- 2491.
2015.12.013.
[19] Stewart PM, Walker BR, Holder G, et al.
11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining
the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome
[J]. J Clin Endocrinol Metab, 1995, 80(12):3617-3620. DOI:
10.1210/jcem.80.12.8530609.
[20] Fan L, Zhuang Y, Wang Y, et al.
Association of hypokalemia with cortisol and ACTH levels in Cushing's disease
[J]. Ann N Y Acad Sci, 2020, 1463(1):60-66. DOI: 10.1111/nyas.14205.
|